The increasing use of anticonvulsants in prophylactic treatment of bipolar disorder.
The medical records of patents with bipolar disorders who received prophylactic drug treatments during three time periods from January 1983 to December 1984, January 1988 to December 1989, and from January 1993 to December 1994, were reviewed retrospectively. The percentage of lithium monotherapy sharply decreased from 96% (51/53) in the first study period to 51.9% (83/160) in the third study period. Carbamazepine monotherapy and combination of lithium and carbamazepine increased from 3.8% in the first study period to 45.6% in the third study period. These results suggest that anticonvulsants may become one of the major drug treatment strategies for bipolar disorder in the future.
Yang
Y Y
YY
Department of Psychiatry, Chang Gung College of Medicine and Technology, and Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Deng
H C
HC
Wang
B H
BH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000517:prevention & control*; D002220:Carbamazepine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000927:Anticonvulsants; D002220:Carbamazepine; D008094:Lithium